XTL Biopharmaceuticals ADR

Nasdaq informed XTL Biopharmaceuticals that its annual report (Form 20‑F) for the fiscal year ended Dec. 31, 2025, was not filed on time, creating an additional delisting reason. The share fell 42% over the past year to $2.51, market capitalization is about $5.9 million, and the company already fails to meet minimum equity and minimum share price requirements. Liquidity is weak (current ratio 0.7) and short‑term liabilities exceed cash and equivalents. XTL can respond to the Nasdaq panel in writing by Monday and has said it will apply for an extension of the suspension, but success is not guaranteed. » More on de.investing.com

XTL Biopharmaceuticals has convened an extraordinary general meeting for 4:00 p.m. local time on 22 June 2026 in the offices of Amit Pollack Matalon & Co. in Tel Aviv. The meeting documents include a notice of meeting and a proxy form; shareholders may also cast their votes by proxy. The announcement is part of the mandatory filing with the U.S. securities regulator, the SEC. » More on de.investing.com

A NASDAQ committee has granted XTL Biopharmaceuticals an exception-based extension, provided the company completes the acquisition of Psyga Bio Ltd. and demonstrates full compliance with all listing requirements by June 30, 2026. XTL has already secured a share purchase agreement for Psyga and a commitment of up to $1.5 million in a private placement; a shareholder vote is to take place no later than June 29, 2026. NASDAQ had previously designated XTL as a “public shell” and cited past violations of minimum bid price rules; after a reverse split the shares now trade above $1. The committee may revise the conditions and requires ongoing reporting of relevant compliance events. » More on de.investing.com